Synopsis
0
CEP/COS
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
22 Jan 2025
// PR NEWSWIRE
22 Jan 2025
// PR NEWSWIRE
09 Jan 2025
// INDPHARMAPOST
16 Oct 2024
// GLOBENEWSWIRE
23 Sep 2024
// FDA
06 Aug 2024
// PR NEWSWIRE
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
ABOUT THIS PAGE
37
PharmaCompass offers a list of Fostamatinib Disodium Hexahydrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Fostamatinib Disodium Hexahydrate manufacturer or Fostamatinib Disodium Hexahydrate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Fostamatinib Disodium Hexahydrate manufacturer or Fostamatinib Disodium Hexahydrate supplier.
PharmaCompass also assists you with knowing the Fostamatinib Disodium Hexahydrate API Price utilized in the formulation of products. Fostamatinib Disodium Hexahydrate API Price is not always fixed or binding as the Fostamatinib Disodium Hexahydrate Price is obtained through a variety of data sources. The Fostamatinib Disodium Hexahydrate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Fostamatinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Fostamatinib, including repackagers and relabelers. The FDA regulates Fostamatinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Fostamatinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Fostamatinib supplier is an individual or a company that provides Fostamatinib active pharmaceutical ingredient (API) or Fostamatinib finished formulations upon request. The Fostamatinib suppliers may include Fostamatinib API manufacturers, exporters, distributors and traders.
click here to find a list of Fostamatinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Fostamatinib DMF (Drug Master File) is a document detailing the whole manufacturing process of Fostamatinib active pharmaceutical ingredient (API) in detail. Different forms of Fostamatinib DMFs exist exist since differing nations have different regulations, such as Fostamatinib USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Fostamatinib DMF submitted to regulatory agencies in the US is known as a USDMF. Fostamatinib USDMF includes data on Fostamatinib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Fostamatinib USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Fostamatinib suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Fostamatinib Drug Master File in Japan (Fostamatinib JDMF) empowers Fostamatinib API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Fostamatinib JDMF during the approval evaluation for pharmaceutical products. At the time of Fostamatinib JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Fostamatinib suppliers with JDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Fostamatinib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Fostamatinib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Fostamatinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Fostamatinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Fostamatinib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Fostamatinib suppliers with NDC on PharmaCompass.
Fostamatinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Fostamatinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Fostamatinib GMP manufacturer or Fostamatinib GMP API supplier for your needs.
A Fostamatinib CoA (Certificate of Analysis) is a formal document that attests to Fostamatinib's compliance with Fostamatinib specifications and serves as a tool for batch-level quality control.
Fostamatinib CoA mostly includes findings from lab analyses of a specific batch. For each Fostamatinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Fostamatinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Fostamatinib EP), Fostamatinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Fostamatinib USP).
Share 
